Drugs / ME TARP peptide vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02362464 | May 2015 → Mar 2022 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ME TARP peptide vaccine | “To assess the long-term safety of repeated TARP peptide vaccination following the use of a 1st generation bivalent (09-C-0139) and a 2nd generation ME TARP peptide vaccine.” NCT02362464 ↗ |
| Modality | Vaccine | “Multi-Epitope (ME) TARP Vaccine” NCT02362464 ↗ |